4[6]Brown MJ,Palmer CR,Castaigne A,et al.Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calci-um-channel blocker or diuretic in the International Nifedipine GITS study Intervention as a goal in hypertension Treatment (INSIGHT)[J].Lancet,2000,356:366.
5Rozzoni D, Muiesan ML, Montani G, et aI. Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring [J]. Am J Hypertens, 1992, 5: 18.
6Louis WJ, Conway EL, Krum H, et al. Comparison of the pharmacokinetics and pharmacodynamics of perlndopriI, cilazapril and enalapril[J]. Clinical and Experinmental Pharmacology and Physiology 1992, 19 (Suppl 19): 55-60.
8Palatini P, Penzo M, Raciopa A, et al. Clinical relevance of nighttime blood pressure and daytime blood pressure variability [J]. J Arch Int Med, 1992, 52: 1855-1860.
9Kikuya M, Hozawa A, Ohokubo J, et al. Prognositic significance of blood pressure and heart rate variabilities [J]. Hypertension, 2000, 36: 901-906.
10Sander D, Kukia C, Klingehofer J. et aI. Relationsbip between circadian blood pressure patterns and progression of early cardiac atherosclerosis [J]. Circulation, 2000, 102: 1536-1541.
4Morel O E,Burry A,Le C P,et al. Effects of Nifedipine-Induced Pulmonary Vasodilatation on Cardiac Receptors andProtein Kinase C Isoforms in the Chronically Hypoxic Rat [J], Pfliigers Arch,2003,446(3) : 356-364.
5Chang H I,Yeh M K. Clinical Development of Liposome-Based Drugs: Formulation, Characterization, andTherapeutic Efficacy [J], International Journal of Nanomedicine, 2012,7 : 49-60.
6Husseini G A, Mjalli F S,Pitt W G. et al. Using Artificial Neural Networks and Model Predictive Control toOptimize Acoustically Assisted Doxorubicin Release from Polymeric Micelles [J]. Technology in Cancer Research and Treatment, 2009,8(6) : 479-488.
